Overview

Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

Status:
Withdrawn
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This proposed study aims to evaluate the efficacy of a daily oral cannabinoid oil preparation in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65 years. The study will also evaluate the relationship between inflammation, anxiety and cannabinoids using biological markers as well as examine the neuro-cognitive effects of cannabinoid treatment.
Phase:
Phase 3
Details
Lead Sponsor:
McMaster University
Collaborator:
MediPharm Labs Corp